Neuramide (Cooper Laboratories, Inc.), a viral inhibitor that is present in crude preparations of tissue extracts and is active against herpesviruses, has been described previously (1, 2) . This inhibitor is also active against a wide range of viruses which are not herpesviruses (unpublished data) and appears to be related to contact-blocking viral inhibitor (CVI), a naturally occurring viral inhibitor which we recently described (3, 4, 6 ; manuscript in preparation). One inhibitory activity of CVI and Neuramide acts to block adsorption of a variety of viruses (3, 6) , although antiviral activity against varicella-zoster virus may occur even when the inhibitor is added to cultures after virus adsorption and penetration have occurred (1) . We show here than Neuramide is highly active against influenza A viruses in vitro. We also show that the primary mode of action of Neuramide against influenza A viruses involves a block in the replication cycle after the virus has been absorbed and that the anti-influenza virus activity is due to a low-molecular-weight molecule.
MATERIALS AND METHODS
Neuramide preparations were obtained from Cooper Laboratories, Inc. Influenza A virus strains HoN, and H2N2 were grown in chicken embryos and maintained at -70°C until they were used. Titration of the anti-influenza virus effects of Neuramide was carried out as followed. Twofold serial dilutions of Neuramide in 0.1-ml volumes were added in triplicate to 96-well microtiter cultures of canine kidney cells (MDCK cells); then 0.025 ml of influenza A virus was added to give an input multiplicity of infection of 100 PFU per cell. Supernatants were collected, and virus yields were determined after 48 h by a hemagglutination assay, which was performed in triplicate (7) . The endpoint activity (1 U) was defined as the last dilution of Neuramide that was capable of inhibiting the hemagglutination yield fourfold compared with the virus control yield.
The standard assay was adapted to study the effect of Neuramide on influenza A virus replication by varying the time of addition of the inhibitor to the MDCK cell monolayers in relation to the virus challenge. At the high multiplicity of infection which we used, all of the cells were infected after 1 h of incubation at 37°C. The different treatment times used during the virus multiplication cycle are shown in Table 1 .
The possible toxic effects of Neuramide on the MDCK cell monolayers were evaluated by three independent methods. These data did not conclusively define which phase of virus replication is affected by the drug. However, since maximal activity occurred when Neuramide was added at 1.0 h, when virus attachment at the high multiplicity of infection was complete, we inferred that the presence of the drug during virus attachment is not required.
To test this hypothesis, Neuramide was added to cell cultures at various times after infection with influenza A virus. After 48 h of incubation, culture supernatants were collected, and hemagglutination yields were determined. The results of two representative experiments carried out with influenza virus strains HoN, and H2N2 are shown in Fig.   1 . Maximal antiviral activity was observed when Neuramide was added to the cultures up to 3 h postinfection, although substantial inhibition was also observed when the drug was added 5 h postinfection. These results suggest that Neuramide is capable of inhibiting the hemagglutination yield of influenza A virus in a phase after penetration of the input virus. However, this type of experiment may not entirely exclude the possibility that virus attachment is affected during subsequent, secondary infectious cycles.
To rule out the latter possibility, we measured the virus yield after a single growth cycle (8 h postinfection) in the presence and absence of Neuramide (Fig. 2) . High, but nontoxic, concentrations of Neuramide which were added after penetration of the virus inhibited the yield of infectious virus by several logs, and significant inhibition (0.7 log1o) was observed even when a concentration of 0.5 U/ml was used. This finding clearly shows that, in contrast to most other natural inhibitors of influenza virus, Neuramide inhibits viral replication at a phase which is after attachment and penetration. Since this characteristic is unusual for natural inhibitors other than interferon (5) and obviously desirable for chemotherapy, we initiated experiments to determine the size of the active molecule.
Neuramide was fractionated by successive molecular weight sieving, using Amicon (type UM, YM, and PM) and Waters membranes that had different pore sizes and were capable of separating various fractions according to molecular weight (>1,000, 500 to 1,000, <500). The integrity and specificity of the filters were monitored by using the following markers having appropriate molecular weights: actinomycin D (molecular weight, 1,255), eosine yellow Table 1 ; thus, 1 U of activity was equal to a 512-fold dilution.
(691), and bromophenol blue (173). In none of the fractions was the level of contamination from neighboring fractions greater than 3%.
Each Neuramide fraction was tested for antiviral activity against influenza A virus. The results of representative experiments are shown in Table 2 . In each case, the highest level of antiviral activity was associated with the least retained of the ultrafiltrates, which contained molecules having the lowest molecular weights (c500). Significant activity (but two-to eight-fold lower) was also present in the next-highest-molecular-weight pools (nominally containing molecules having molecular weights of 500 to 1000) in each experiment. From these data, it was impossible to determine whether the heterogeneity which we observed was due to cross-contamination of the adjacent molecular weight pools or to the presence of two populations of molecules, each of which exerted an antiviral effect against influenza A virus. Experiments are currently underway to clarify this point. However, it is clear that the anti-influenza virus activity of Neuramide resides in a small molecule(s) having a molecular weight(s) of less than 1,000.
In conclusion, our experiments established that Neuramide contains an antiviral substance which is small and is active against influenza A viruses at concentrations which 
